Cytokinetics Stock Jumps To Higher RS Level
On Thursday, Cytokinetics (CYTK) cleared a key execution benchmark, with its Relative Strength (RS) Rating going into the 90 or more percentile with an improvement to 99, an increment from 89 the other day. The clinical-stage biotech organization shot up 83% on Wednesday in the wake of declaring positive outcomes from a Stage 3 investigation … Read more